Gunnar Gottschalk

C. Gunner Gottschalk, M.S., is a student at Rush University Medical Center, Chicago, Illinois and a member of the Board of Directors at Simmaron Research, a non-profit organization based in Incline Village, Nevada, which works to advance translational science in treating neuroimmune diseases like CFS/ME.

In 2012, Gottschalk was the Clinical Coordinator for years I and II of the CDC Multi-site Clinical Assessment of CFS. The project's aim was to characterize patients with CFS or myalgic encephalomyelitis (ME) in clinical practices of clinicians with expertise in CFS/ME. Team members included Andreas Kogelnik, Lucinda Bateman, and Nancy Klimas.

In 2012, Gottschalk was the Cohort Recruitment Project Clinical Coordinator at the Chronic Fatigue Initiative at the Hutchins Family Foundation for the project to develop a clinical and biosample database to enable discovery of pathogens and pathogenic mechanisms in Chronic Fatigue Syndrome.

Notable Studies

 * 2016, Cytokine network analysis of cerebrospinal fluid in myalgic encephalomyelitis/chronic fatigue syndrome.
 * 2015, Cytokines in the Cerebrospinal Fluids of Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
 * 2015, Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome. Abstract
 * 2015, Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study. Abstract
 * 2015, Distinct plasma immune signatures in ME/CFS are present early in the course of illness  FULL TEXT"'Abstract: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is an unexplained incapacitating illness that may affect up to 4 million people in the United States alone. There are no validated laboratory tests for diagnosis or management despite global efforts to find biomarkers of disease. We considered the possibility that inability to identify such biomarkers reflected variations in diagnostic criteria and laboratory methods as well as the timing of sample collection during the course of the illness. Accordingly, we leveraged two large, multicenter cohort studies of ME/CFS to assess the relationship of immune signatures with diagnosis, illness duration, and other clinical variables. Controls were frequency-matched on key variables known to affect immune status, including season of sampling and geographic site, in addition to age and sex. We report here distinct alterations in plasma immune signatures early in the course of ME/CFS (n = 52) relative to healthy controls (n = 348) that are not present in subjects with longer duration of illness (n = 246). Analyses based on disease duration revealed that early ME/CFS cases had a prominent activation of both pro- and anti-inflammatory cytokines as well as dissociation of intercytokine regulatory networks. We found a stronger correlation of cytokine alterations with illness duration than with measures of illness severity, suggesting that the immunopathology of ME/CFS is not static. These findings have critical implications for discovery of interventional strategies and early diagnosis of ME/CFS.'"

Talks and Interviews

 * 2013, Gave oral presentation on the therapeutic potential of cidofovir at the HHV-6/7 International Conference 2013, Paris France
 * 2013, ME/CFS Alert Episode 49 - [[ME/CFS Alert] - Interview with Gunnar Gottschalk]
 * 2012, ME/CFS Alert Episode 30 - [[ME/CFS Alert] - Gunnar Gottschalk on ME/CFS Research and Challenges]

Online Presence

 * 2013, Taking Fundraising for ME/CFS Research to New Heights - Gunner Gottschalk and [[Robert Miller] skydive to raise funds for Simmaron Research]